Coinfected With HIV and Hep C? Time To Party Like It’s 1996
The hep C revolution is upon us. Echoing the 1996 introduction of HIV antiretroviral cocktails, 2014 is all but certain to go down in history as HCV’s watershed year. Keep an eye out for Gilead’s ledipasvir and Bristol-Myers Squibb’s daclatasvir. They can be used interferon free and allow for 95%+ cure rates after as little as six to 12 weeks of treatment.
A ‘government’ video of the device at work shows what looks like a hand exerciser connected to a long, swiveling antennae, as well as several patients hooked up to a box-like machine. Part of the Army treatment also involves ground meat.
Obamacare: Not So Affordable for People With HIV and Hep C
A myriad of insurers across the country have designed Affordable Care Act plans that leave out the “affordable” angle and leave those with chronic health conditions with prohibitively expensive out-of-pocket costs, as well as restricted medication and health provider options. Many people with HIV or HCV will hit their maximum out-of-pocket cap within the first few months of their insurance plan’s policy year, a figure that can climb as high as $6,350.
Russia is home to the world’s fastest-growing HIV epidemic. Driven by injection drug use, it is now becoming generalized. If you are a person who injects drugs in Russia, you likely have HIV, hepatitis C, and more often than not, tuberculosis.
Although the Russian constitution grants the right to free access to health services in government facilities, it does not provide effective care to those who have these multiple infections. And it bans opioid substitution therapy—the gold standard for opioid dependance treatment.
How the ACA Builds Barriers to HIV, Hep C Treatment
Discriminatory practices by insurers, high drug prices from pharmaceutical companies and no clear federal guidelines for co-payments are to blame for those consistently costly plans under the Affordable Care Act.
What Does This “Government Shutdown” Mean for HIV/AIDS Drugs?
Turns out it’s not so good. With Congress locked in a critical battle over fiscal talks, the looming threat of a government shutdown on October 1 (tomorrow!) may spell potential delays in FDA approvals of new drugs, such as Viiv’s Tivicay and Epzicom as well as the Hep C pharma field.
Treatment News: Women Spontaneously Clear Hep C Better Than Men
Spontaneous clearance of acute hepatitis C virus (HCV)—when viral levels drop to undetectable without drug treatment during the early phase of infection—is twice as likely to occur in women than in men.
David Kwiatkowski stole painkiller syringes and injected himself with them, which tainted them with hep C. He then filled them with saline and put them back for medical use.